BofA lowered the firm’s price target on Boston Scientific (BSX) to $105 from $120 and keeps a Buy rating on the shares. The firm still sees Boston Scientific as a share gainer in total EP market in 2026 and while the company “got a ding in Q4,” it remains “one of the highest growth/quality medtech companies with strong EPS compounding,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $115 from $140 at Mizuho
- Boston Scientific price target lowered to $96 from $112 at Evercore ISI
- Boston Scientific price target lowered to $110 from $125 at Stifel
- Boston Scientific price target lowered to $100 from $135 at JPMorgan
- Boston Scientific price target lowered to $94 from $125 at Wells Fargo